Evidence map›Paper›PMID 41607769›Full record

ArticleWorld journal of gastrointestinal oncology2026

Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.

Toshihiko Matsumoto, Soma Sugimoto, Reo Omori, Chinatsu Makiyama, Akio Nakasya, Hiroki Nagai, Hisateru Yasui, Reiji Higashi, Akitoshi Sasamoto, Hironaga Satake

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toshihiko MatsumotoDepartment of Medical Oncology, Ichinomiyanishi Hospital, Ichinomiya 4940001, Aichi, Japan.
Soma SugimotoDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe 650-0047, Hyōgo, Japan.
Reo OmoriDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe 650-0047, Hyōgo, Japan.
Chinatsu MakiyamaDepartment of Medical Oncology, Ichinomiyanishi Hospital, Ichinomiya 4940001, Aichi, Japan.
Akio NakasyaDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe 650-0047, Hyōgo, Japan.
Hiroki NagaiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe 650-0047, Hyōgo, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe 650-0047, Hyōgo, Japan.
Reiji HigashiDepartment of Gastroenterology, Ichinoimiya Nishi Hospital, Ichinomiya 4940001, Aichi, Japan.
Akitoshi SasamotoDepartment of Surgery, Ichinoimiya Nishi Hospital, Ichinomiya 4940001, Aichi, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe 650-0047, Hyōgo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy with an immune checkpoint inhibitor is one of the standard regimens for treating advanced gastric cancer (AGC). Ascites and peritoneal dissemination are common complications and poor prognostic factors of AGC; however, reports regarding its efficacy and safety in patients with AGC and massive ascites are limited.

aimTo evaluate the safety and efficacy of nivolumab combined with chemotherapy in patients with AGC and ascites.

methodsWe retrospectively collected clinical data from 124 patients with AGC who received chemotherapy plus nivolumab as first-line treatment from July 2017 to December 2024. Based on computed tomography scans, massive or moderate ascites were classified as high ascites burden (HAB), whereas mild or no ascites were classified as low ascites burden.

resultsAscites was detected in 47 patients (38%); 26 (21%) were classified into the HAB group. Patients in the HAB group exhibited a significantly poorer performance status, a higher prevalence of diffuse-type histology, and lower programmed cell death ligand 1 (PD-L1) expression. Combination therapy with FOLFOX and neutropenia was significantly more common in the HAB group. Progression-free survival (PFS) (4.4 months

conclusionNivolumab plus chemotherapy demonstrated modest efficacy and acceptable toxicity in patients with AGC and HAB.

Indexed as

AscitesChemotherapy plus nivolumabGastric cancerImmune checkpoint inhibitorNivolumab

Identifiers

PMID41607769
PMCPMC12836160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.